An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Butterfly Network to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Butterfly Network, Inc. (NYSE: BFLY) will participate in the 42nd Annual J.P. Morgan Healthcare Conference on January 8-11, 2024, in San Francisco. Joseph DeVivo, President & Chief Executive Officer, and Heather Getz, Executive Vice President & Chief Financial Officer, will present on January 11, 2024, at 9:00 AM PST. A webcast of the presentation will be available on the Butterfly investor website.
Positive
None.
Negative
None.
NEW YORK & BURLINGTON, Mass.--(BUSINESS WIRE)--
Butterfly Network, Inc. (NYSE: BFLY) (“Butterfly”) a digital health company transforming care with handheld, whole-body ultrasound and intuitive software, today announced that it will participate at the 42nd Annual J.P. Morgan Healthcare Conference taking place January 8-11, 2024, in San Francisco, California. Joseph DeVivo, President & Chief Executive Officer, and Heather Getz, Executive Vice President & Chief Financial Officer, will present on Thursday, January 11, 2024, at 9:00 AM PST.
A webcast of the presentation will be available in the Events & Presentations section of the Butterfly investor website.
To schedule a one-on-one meeting with Mr. DeVivo and Ms. Getz, please reach out to your J.P. Morgan representative.
About Butterfly Network
Founded by Dr. Jonathan Rothberg in 2011 and listed on the New York Stock Exchange through a business combination with Longview Acquisition Corp., Butterfly created the world's first handheld, single probe whole-body ultrasound system using semiconductor technology, the Butterfly iQ+. Butterfly's mission is to democratize medical imaging and contribute to the aspiration of global health equity, making high-quality ultrasound affordable, easy-to-use, globally accessible, and intelligently connected, including for the 4.7 billion people around the world lacking access to ultrasound. Through its proprietary Ultrasound-on-Chip™ technology, Butterfly is paving the way for earlier detection and remote management of health conditions around the world. The Butterfly iQ+ can be purchased today by trained healthcare practitioners in areas including, but not limited to, parts of Africa, Asia, Australia, Europe, the Middle East, North America and South America; to learn more about available countries, visit: www.butterflynetwork.com/choose-your-country.
When will Butterfly Network, Inc. (NYSE: BFLY) participate in the 42nd Annual J.P. Morgan Healthcare Conference?
Butterfly Network, Inc. (NYSE: BFLY) will participate in the 42nd Annual J.P. Morgan Healthcare Conference on January 8-11, 2024, in San Francisco.
Who will be presenting at the conference for Butterfly Network, Inc. (NYSE: BFLY)?
Joseph DeVivo, President & Chief Executive Officer, and Heather Getz, Executive Vice President & Chief Financial Officer, will present on January 11, 2024, at 9:00 AM PST.
Where can I watch the presentation by Butterfly Network, Inc. (NYSE: BFLY)?
A webcast of the presentation will be available on the Butterfly investor website.
butterfly network operates at the cutting edge of multiple engineering and scientific disciplines and strives to bring together world-class talent in computer science, physics, and electrical engineering. the company is privately held and well funded by a small group of extraordinarily successful serial entrepreneurs. the company is in the rare position of being able to focus 100% of its efforts on product and intellectual property development rather than fundraising.
